Mayo Clinic Scientists Explore 'Sugar Coating' Strategy to Protect Insulin-Producing Cells

Mayo Clinic researchers have discovered an unexpected connection between cancer immunology and type 1 diabetes. While studying how cancer cells evade the immune system, they found that malignant cells coat themselves in a sugar molecule called sialic acid. This coating acts as a disguise, making cancer cells appear invisible to immune cells that would normally destroy them.

The research team, led by immunology researcher Virginia Shapiro, Ph.D., wondered: could this same strategy protect the cells that type 1 diabetes damages? Their findings, published in the Journal of Clinical Investigation, suggest it might be possible.

Type 1 diabetes is an autoimmune condition affecting approximately 1.3 million people in the United States. In this disease, the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Once these cells are destroyed, the body can no longer produce the insulin needed to regulate blood sugar. The condition results from both genetic factors and other influences.

In preclinical models—laboratory-based studies that don't yet involve people—Mayo researchers tested whether they could engineer beta cells by coating them with sialic acid using an enzyme called ST8Sia6. The goal was to make these beta cells appear non-threatening to the immune system, much like cancer cells do.

According to Dr. Shapiro, the results were encouraging. 'Our findings show that it's possible to engineer beta cells that do not prompt an immune response,' she said. The research demonstrates that this approach is theoretically feasible as a direction for future work.

This research is in its earliest stages. The work has only been tested in laboratory models and has not yet been studied in people. There is no current treatment available based on these findings, and much more research is needed before this approach could potentially help patients.

The study does, however, open a new avenue for scientists to explore: the possibility of protecting beta cells from immune attack by harnessing mechanisms that nature already uses in other contexts. Future work will need to determine whether this strategy can be safely and effectively applied in people with type 1 diabetes.

Origin: Mayo Clinic News Network (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.